Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2025Acta Haematologica

Discrepancies in Treatment Goals and Concerns Regarding Disease Management between Patients with Myeloproliferative Neoplasms and Hematologists in China: Analysis from a Multicenter Cross-Sectional Survey

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJunling ZhuangHSHongxia ShiXLXiaoli Liu

Discussion

Loading...

Member takes

Overview

Cross-sectional survey revealed differing treatment goals in myeloproliferative neoplasms between patients and hematologists, suggesting enhanced patient-physician communication is crucial.

Key Points

  • Patients with myeloproliferative neoplasms identified distinct treatment goals compared to hematologists, indicating a gap in disease management perceptions.
  • Almost half of patients emphasized cure and healthy blood counts as goals, while physicians focused on preventing thrombotic events and improving quality of life.
  • Analysis involved 1,645 patients with myeloproliferative neoplasms and 715 hematologists, exploring concerns and treatment goals.
  • Understanding these discrepancies can improve treatment satisfaction and compliance, emphasizing the need for better communication mechanisms.

Cite This Study

Zhuang et al. (2025) studied this question.

synapsesocial.com/papers/68f8a381c0c01e5ef8abdcb8https://doi.org/10.1159/000547173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)2006 · 402 citations
  2. 2Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms2021 · 8 citations
  3. 3Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States2018 · 40 citations
  4. 4A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,108 citations
  5. 5A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment2012 · 279 citations